Cardiotoxicity associated with cancer therapy: Pathophysiology
and prevention
Cardiotoxicity associated with cancer therapy:
Pathophysiologyand preventionIntegrantes: Laureano Gmez Vivian
Herrera Cristiam RoaAntineoplastic drugs and cardiomyopathy
Risk factors
Trastuzumab induces ventricular dysfunction
Radiotherapy-induced cardiotoxicity
Electrical conduction
Principal techniques used for monitoring cardiotoxicity in
clinical practiceEndomyocardial
biopsyEchocardiographyRadionuclideAngiographyElectrocardiographyTissue
DopplerStress EchocardiographyMagnetic resonance ImagingComputed
tomographyScintigraphyBiomarkersEndothelial damageGenetic
analysis
ConclusionThere is no consensus on standardizing the monitoring
of cardiac function in these patients.There is no reliable models
able to predict the risk of cardiotoxicity.Careful management and
assessment of cardiac risk is essential in these patients, and the
long-term effects of different treatments require further study. It
is increasingly important to establish dynamic partnerships between
oncologists and cardiologists in order to reduce mortality and
improve patients quality of life, while maintaining the efficacy of
the treatment.
